AstraZeneca PLC (AZN) vs Johnson & Johnson (JNJ)
- AstraZeneca PLC AZN 186.52 −0.18%
- Johnson & Johnson JNJ 273.34 +0.37%
AstraZeneca PLC and Johnson & Johnson are both Drug Manufacturers General companies. Johnson & Johnson is the larger, with a market value of $655.6B against $289.8B — 2.3× the size. AstraZeneca PLC trades at the lower P/E: 26.3× against 41.3×. Johnson & Johnson grew revenue faster over the last twelve months: 7.80% against 7.32%. AstraZeneca PLC has the higher net margin (17.7% vs 16.2%) and the higher return on invested capital (12.3% vs 11.1%). Both pay a dividend; Johnson & Johnson yields more (1.94% vs 1.71%). Across the 23 metrics below, AstraZeneca PLC leads on 14 and Johnson & Johnson on 9.
Valuation
Profitability
| Metric | AZN | JNJ | Drug Manufacturers General median |
|---|---|---|---|
| Gross margin | 81.94% | 67.56% | 73.01% |
| Operating margin | 23.68% | 19.72% | 18.34% |
| Net margin | 17.68% | 16.20% | 7.31% |
| Free cash flow margin | 10.15% | 21.13% | 18.52% |
| Return on equity | 22.56% | 20.02% | 5.80% |
| Return on assets | 9.41% | 8.25% | 2.28% |
| Return on invested capital | 12.31% | 11.07% | 6.26% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack